Jonathan E. Phillips

Bleomycin Induces Molecular Changes Directly Relevant to Idiopathic Pulmonary Fibrosis: A Model for “Active” Disease

Ruoqi Peng, Sriram Sridhar, Gaurav Tyagi et al. · PLoS ONE · 2013 · 222 citations · Full text

Acute Lung Injury, Inflammatory Lung Disease, Advanced Lung Disease +19

A Novel, Orally Active CXCR1/2 Receptor Antagonist, Sch527123, Inhibits Neutrophil Recruitment, Mucus Production, and Goblet Cell Hyperplasia in Animal Models of Pulmonary Inflammation

Richard W. Chapman, Michael Minnicozzi, Chander Celly et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 140 citations

Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways

Kent Miner, Katja Labitzke, Benxian Liu et al. · Frontiers in Pharmacology · 2019 · 132 citations · Full text

Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis

Xiaoyan Tang, Ruoqi Peng, Jonathan E. Phillips et al. · American Journal Of Pathology · 2013 · 129 citations · Full text

Translational Medicine, Antifibrotic Therapy, Fibrosis +11

Regulation of vocal fold transepithelial water fluxes

Kimberly V. Fisher, Alvin Telser, Jonathan E. Phillips et al. · Journal of Applied Physiology · 2001 · 62 citations · Full text